ClinicalTrials.gg
Active, not recruitingNCT03171311OCTOBERUpdated Nov 6, 2026

The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)

An interventional study of Angiographic guided PCI and OCT guided PCI in Ischaemic Heart Disease and Ischemic Heart Disease, sponsored by Aarhus University Hospital Skejby. Active, not recruiting at 38 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Aarhus University Hospital Skejby · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,201
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby — none open to participants now, 4 under way, none of them phase 3. Coronary Artery Disease · Aarhus University Hospital Skejby.

Enrollment
7th of 15
1,201 · median 425
Started
2017
with 2 others
No phase
11 of 18
none open now
Registered
14th of 18
by date

Among the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby, this one is the 7th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2017, is one of 11 with no phase, and was the 14th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

None of the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby is open now. The open studies under Coronary Artery Disease, anywhere →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby as a file.
02

Study summary

The purpose is to compare median two-year clinical outcome after OCT guided vs. standard guided revascularization of patients requiring complex bifurcation stent implantation

Read the detailed description

Coronary bifurcation lesions with stenosis in a large side branch may require complex stent implantation techniques with an elevated risk of suboptimal treatment results. Intra vascular optical coherence tomography (OCT) enables improved procedural control of correctable factors and may lead to optimized implantation results.

It is unknown if routine, systematic use of OCT scans during complex bifurcation stenting improves clinical outcome but present available evidence indicates advantages of OCT guidance that could translate into improved clinical outcome.

Hypothesis: Systematic OCT guided revascularization of patients with bifurcation lesions requiring complex stent implantation provides superior two-year clinical outcome compared to standard revascularization by PCI.

Methods: Investigator initiated and investigator sponsored, randomized (1:1), controlled, prospective, multicenter, superiority trial. Randomization is stratified for 1) Left main or non-Left main artery disease, and 2) up-front planned one-stent technique with kissing balloon inflation, or a two-stent technique.

Systematic OCT guidance is detailed for five complex stent implantation techniques. Standard treatment is angiographic based with optional use of intravascular ultrasound (IVUS).

03

Conditions studied

  • Ischaemic Heart Disease
  • Ischemic Heart Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable angina pectoris, unstable angina pectoris, clinically stable non-STEMI.
  • Age ≥18 yrs.
  • Abel to provide written and willing to comply with the specified follow-up contacts.

Angiographic inclusion criteria:

  • Native coronary bifurcation de novo lesion
  • More than 50% diameter stenosis in the main vessel (MV)
  • More than 50% diameter stenosis in the side branch (SB) within 5 mm of the ostium.
  • Reference size at least 2.75 mm in the main vessel (MV) and ≥2.5 mm in the SB.

Functional inclusion criteria:

Functional significance of the main vessel lesion or documented ischemia of the main vessel territory or other objective documentation of lesion significance. Objective evidence of ischemia is required for all treated lesions except for lesions with more than 80% diameter stenosis that may be considered significant.

Procedural inclusion criteria:

Indication for two-stent technique or one-stent technique with kissing balloon inflation

Exclusion criteria

Exclusion Criteria:

  • STEMI within 72 hours
  • Cardiogenic shock
  • Prior coronary artery bypass grafting (CABG) or planned CABG
  • Renal failure with (GFR) \<50 mL/min per 1.73 m2
  • Active bleeding or coagulopathy
  • \< 2 years
  • \< 30%
  • (NYHA) class > II
  • Relevant allergies (aspirin, clopidogrel, ticagrelor, contrast compounds, everolimus).

Angiographic exclusion criteria:

  • Severe tortuosity around target bifurcation
  • Chronic total occlusions
  • Massive thrombus in Left main coronary artery
  • Medina 0.0.1 lesions
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,201 participants (actual)

Study arms

  • Active comparator
    Angiographic guided PCI

    Angiographic guided PCI is revascularization by percutaneous coronary intervention (PCI) and optional use of intravascular ultrasound (IVUS).

    Procedure: Angiographic guided PCI

  • Experimental
    OCT guided PCI

    OCT guided PCI is percutaneous coronary intervention (PCI) guided by systematic use of intravascular optical coherence tomography (OCT)

    Procedure: OCT guided PCI

Interventions

  • ProcedureAngiographic guided PCI

    Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques

    Also known as: PCI, percutaneous transluminal coronary angioplasty (PTCA)

  • ProcedureOCT guided PCI

    OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans

    Also known as: OCT

06

What researchers measure

Primary outcomes

  1. Combined endpoint of major adverse cardiac events (MACE)

    Composite of cardiac death, target lesion myocardial infarction, ischaemic driven target lesion revascularization

    Time frame: 24 months

Secondary outcomes

  1. Study bifurcation oriented composite endpoint

    Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation

    Time frame: 1 month

  2. Study bifurcation oriented composite endpoint

    Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation

    Time frame: 12 months

  3. Study bifurcation oriented composite endpoint

    Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation

    Time frame: 24 months

  4. Study bifurcation oriented composite endpoint

    Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation

    Time frame: 36 months

  5. Study bifurcation oriented composite endpoint

    Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation

    Time frame: 48 months

  6. Study bifurcation oriented composite endpoint

    Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation

    Time frame: 60 months

  7. Patient oriented composite endpoint

    Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke

    Time frame: 1 month

  8. Patient oriented composite endpoint

    Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke

    Time frame: 12 months

  9. Patient oriented composite endpoint

    Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke

    Time frame: 24 months

  10. Patient oriented composite endpoint

    Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke

    Time frame: 36 months

  11. Patient oriented composite endpoint

    Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke

    Time frame: 48 months

  12. Patient oriented composite endpoint

    Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke

    Time frame: 60 months

  13. All-cause mortality

    Death of any cause including cardiac deaths and non-natural causes of death

    Time frame: 1 month

  14. All-cause mortality

    Death of any cause including cardiac deaths and non-natural causes of death

    Time frame: 12 months

  15. All-cause mortality

    Death of any cause including cardiac deaths and non-natural causes of death

    Time frame: 24 months

  16. All-cause mortality

    Death of any cause including cardiac deaths and non-natural causes of death

    Time frame: 36 months

  17. All-cause mortality

    Death of any cause including cardiac deaths and non-natural causes of death

    Time frame: 48 months

  18. All-cause mortality

    Death of any cause including cardiac deaths and non-natural causes of death

    Time frame: 60 months

  19. All-cause mortality

    Death of any cause including cardiac deaths and non-natural causes of death

    Time frame: 120 months

  20. Cardiac death

    Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes

    Time frame: 1 month

  21. Cardiac death

    Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes

    Time frame: 12 months

  22. Cardiac death

    Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes

    Time frame: 24 months

  23. Cardiac death

    Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes

    Time frame: 36 months

  24. Cardiac death

    Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes

    Time frame: 48 months

  25. Cardiac death

    Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes

    Time frame: 60 months

  26. Myocardial infarction

    Procedure and non-procedure related myocardial infarction

    Time frame: 1 month

  27. Myocardial infarction

    Procedure and non-procedure related myocardial infarction

    Time frame: 12 months

  28. Myocardial infarction

    Procedure and non-procedure related myocardial infarction

    Time frame: 24 months

  29. Myocardial infarction

    Procedure and non-procedure related myocardial infarction

    Time frame: 36 months

  30. Myocardial infarction

    Procedure and non-procedure related myocardial infarction

    Time frame: 48 months

  31. Myocardial infarction

    Procedure and non-procedure related myocardial infarction

    Time frame: 60 months

  32. Stent Thrombosis

    Definite, possible or probable

    Time frame: 1 month

  33. Stent Thrombosis

    Definite, possible or probable

    Time frame: 12 months

  34. Stent Thrombosis

    Definite, possible or probable

    Time frame: 24 months

  35. Stent Thrombosis

    Definite, possible or probable

    Time frame: 36 months

  36. Stent Thrombosis

    Definite, possible or probable

    Time frame: 48 months

  37. Stent Thrombosis

    Definite, possible or probable

    Time frame: 60 months

  38. Target lesion myocardial infarction

    Myocardial infarction related to an index treated lesion

    Time frame: 1 month

  39. Target lesion myocardial infarction

    Myocardial infarction related to an index treated lesion

    Time frame: 12 months

  40. Target lesion myocardial infarction

    Myocardial infarction related to an index treated lesion

    Time frame: 24 months

  41. Target lesion myocardial infarction

    Myocardial infarction related to an index treated lesion

    Time frame: 36 months

  42. Target lesion myocardial infarction

    Myocardial infarction related to an index treated lesion

    Time frame: 48 months

  43. Target lesion myocardial infarction

    Myocardial infarction related to an index treated lesion

    Time frame: 60 months

  44. Target lesion revascularisation

    Coronary artery bypass grafting or PCI of target lesion

    Time frame: 1 month

  45. Target lesion revascularisation

    Coronary artery bypass grafting or PCI of target lesion

    Time frame: 12 months

  46. Target lesion revascularisation

    Coronary artery bypass grafting or PCI of target lesion

    Time frame: 24 months

  47. Target lesion revascularisation

    Coronary artery bypass grafting or PCI of target lesion

    Time frame: 36 months

  48. Target lesion revascularisation

    Coronary artery bypass grafting or PCI of target lesion

    Time frame: 48 months

  49. Target lesion revascularisation

    Coronary artery bypass grafting or PCI of target lesion

    Time frame: 60 months

  50. Target bifurcation myocardial infarction

    Myocardial infarction related to the index bifurcation

    Time frame: 1 month

  51. Target bifurcation myocardial infarction

    Myocardial infarction related to the index bifurcation

    Time frame: 12 months

  52. Target bifurcation myocardial infarction

    Myocardial infarction related to the index bifurcation

    Time frame: 24 months

  53. Target bifurcation myocardial infarction

    Myocardial infarction related to the index bifurcation

    Time frame: 36 months

  54. Target bifurcation myocardial infarction

    Myocardial infarction related to the index bifurcation

    Time frame: 48 months

  55. Target bifurcation myocardial infarction

    Myocardial infarction related to the index bifurcation

    Time frame: 60 months

  56. Target bifurcation revascularisation

    Coronary artery bypass grafting or PCI of target bifurcation

    Time frame: 1 month

  57. Target bifurcation revascularisation

    Coronary artery bypass grafting or PCI of target bifurcation

    Time frame: 12 months

  58. Target bifurcation revascularisation

    Coronary artery bypass grafting or PCI of target bifurcation

    Time frame: 24 months

  59. Target bifurcation revascularisation

    Coronary artery bypass grafting or PCI of target bifurcation

    Time frame: 36 months

  60. Target bifurcation revascularisation

    Coronary artery bypass grafting or PCI of target bifurcation

    Time frame: 48 months

  61. Target bifurcation revascularisation

    Coronary artery bypass grafting or PCI of target bifurcation

    Time frame: 60 months

  62. Target vessel revascularisation

    Coronary artery bypass grafting or PCI of target vessel

    Time frame: 1 month

  63. Target vessel revascularisation

    Coronary artery bypass grafting or PCI of target vessel

    Time frame: 12 months

  64. Target vessel revascularisation

    Coronary artery bypass grafting or PCI of target vessel

    Time frame: 24 months

  65. Target vessel revascularisation

    Coronary artery bypass grafting or PCI of target vessel

    Time frame: 36 months

  66. Target vessel revascularisation

    Coronary artery bypass grafting or PCI of target vessel

    Time frame: 48 months

  67. Target vessel revascularisation

    Coronary artery bypass grafting or PCI of target vessel

    Time frame: 60 months

  68. Any revascularisation

    Any repeat revascularization except staged revascularization planned during the index procedure

    Time frame: 1 month

  69. Any revascularisation

    Any repeat revascularization except staged revascularization planned during the index procedure

    Time frame: 12 months

  70. Any revascularisation

    Any repeat revascularization except staged revascularization planned during the index procedure

    Time frame: 24 months

  71. Any revascularisation

    Any repeat revascularization except staged revascularization planned during the index procedure

    Time frame: 36 months

  72. Any revascularisation

    Any repeat revascularization except staged revascularization planned during the index procedure

    Time frame: 48 months

  73. Any revascularisation

    Any repeat revascularization except staged revascularization planned during the index procedure

    Time frame: 60 months

  74. CCS angina class

    Canadian Cardiovascular Society (CCS) grading of angina pectoris

    Time frame: 1 month

  75. CCS angina class

    Canadian Cardiovascular Society (CCS) grading of angina pectoris

    Time frame: 12 months

  76. CCS angina class

    Canadian Cardiovascular Society (CCS) grading of angina pectoris

    Time frame: 24 months

  77. CCS angina class

    Canadian Cardiovascular Society (CCS) grading of angina pectoris

    Time frame: 36 months

  78. CCS angina class

    Canadian Cardiovascular Society (CCS) grading of angina pectoris

    Time frame: 48 months

  79. CCS angina class

    Canadian Cardiovascular Society (CCS) grading of angina pectoris

    Time frame: 60 months

  80. Contrast volume

    Contrast volume

    Time frame: Baseline, after final baseline procedure

  81. Procedure time

    Procedure time

    Time frame: Baseline, after final baseline procedure

  82. Fluoroscopy time

    Fluoroscopy time

    Time frame: Baseline, after final baseline procedure

  83. Number of stents implanted in target lesion

    Number of stents implanted in target lesion

    Time frame: Baseline, after final baseline procedure

  84. Number of stents implanted in non-target lesion

    Number of stents implanted in non-target lesion

    Time frame: Baseline, after final baseline procedure

  85. Total stent length in target lesion

    Total stent length in target lesion

    Time frame: Baseline, just after final baseline procedure

  86. Total stent length in total

    Total stent length in total

    Time frame: Baseline, just after final baseline procedure

  87. Procedural success

    TIMI III flow and less than 30% diameter stenosis in target segments

    Time frame: Baseline, just after final baseline procedure

  88. OCT-guiding group: Successful final OCT acquisition in MV

    For OCT-guided enrollments. Successful final OCT acquisition in main vessel. Success defined as analyzable stented segment.

    Time frame: Baseline, just after final baseline procedure

  89. OCT-guiding group: Successful final OCT acquisition in SB

    For OCT-guided enrollments. Successful final OCT acquisition in side branch. Success defined as analyzable stented segment.

    Time frame: Baseline, just after final baseline procedure

  90. OCT-guiding group: Successful treatment specific OCT acquisitions

    OCT performed succesfully in protocol-defined vessels at all protocol-defined time-points during baseline procedure

    Time frame: Baseline, after final baseline procedure

  91. Post-PCI minimal lumen diameter in the stented proximal main vessel segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the stented proximal main vessel segment

    Time frame: Baseline, after final baseline procedure

  92. Post-PCI minimal lumen diameter in the stented distal main vessel segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the stented distal main vessel segment

    Time frame: Baseline, after final baseline procedure

  93. Post-PCI minimal lumen diameter in the treated side branch vessel segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the treated (stent or balloon) side branch vessel segment

    Time frame: Baseline, just after final baseline procedure

  94. Post-PCI minimal lumen diameter in the proximal main vessel edge segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the proximal main vessel edge segment (within 5 mm from the stent)

    Time frame: Baseline, just after final baseline procedure

  95. Post-PCI minimal lumen diameter in the distal main vessel edge segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the distal main vessel edge segment (within 5 mm from the stent)

    Time frame: Baseline, just after final baseline procedure

  96. Post-PCI minimal lumen diameter in the side branch vessel edge segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the side branch vessel edge segment (within 5 mm from stent or balloon)

    Time frame: Baseline, just after final baseline procedure

  97. Post-PCI minimal lumen diameter in the stented bifurcation core segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the stented bifurcation core segment

    Time frame: Baseline, after final baseline procedure

  98. Post-PCI minimal lumen diameter in the stented distal main vessel ostium segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the stented distal main vessel ostium segment

    Time frame: Baseline, just after final baseline procedure

  99. Post-PCI minimal lumen diameter in the treated side branch vessel ostium segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the treated side branch vessel ostium segment

    Time frame: Baseline, just after final baseline procedure

  100. Post-PCI diameter stenosis in the stented proximal main vessel segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the stented proximal main vessel segment

    Time frame: Baseline, just after final baseline procedure

  101. Post-PCI diameter stenosis in the stented distal main vessel segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the stented distal main vessel segment

    Time frame: Baseline, after final baseline procedure

  102. Post-PCI diameter stenosis in the treated side branch vessel segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the treated (stent or balloon) side branch vessel segment

    Time frame: Baseline, after final baseline procedure

  103. Post-PCI diameter stenosis in the proximal main vessel edge segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the proximal main vessel edge segment (within 5 mm from the stent)

    Time frame: Baseline, just after final baseline procedure

  104. Post-PCI diameter stenosis in the distal main vessel edge segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the distal main vessel edge segment (within 5 mm from the stent)

    Time frame: Baseline, just after final baseline procedure

  105. Post-PCI diameter stenosis in the side branch vessel edge segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the side branch vessel edge segment (within 5 mm from stent or balloon)

    Time frame: Baseline, just after final baseline procedure

  106. Post-PCI diameter stenosis in the stented bifurcation core segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the stented bifurcation core segment

    Time frame: Baseline, just after final baseline procedure

  107. Post-PCI diameter stenosis in the stented distal main vessel ostium segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the stented distal main vessel ostium segment

    Time frame: Baseline, just after final baseline procedure

  108. Post-PCI diameter stenosis in the treated side branch ostium segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the treated side branch ostium segment

    Time frame: Baseline, just after final baseline procedure

  109. Post-PCI minimal lumen diameter in non-bifurcation target stented segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in non-bifurcation target stented segment

    Time frame: Baseline, after final baseline procedure

  110. Post-PCI minimal lumen diameter in non-bifurcation target proximal edge segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in non-bifurcation target proximal edge segment (within 5mm fra stent)

    Time frame: Baseline, after final baseline procedure

  111. Post-PCI minimal lumen diameter in non-bifurcation target distal edge segment

    Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in non-bifurcation target distal edge segment (within 5mm fra stent)

    Time frame: Baseline, just after final baseline procedure

  112. Post-PCI diameter stenosis in non-bifurcation target stented segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in non-bifurcation target stented segment

    Time frame: Baseline, just after final baseline procedure

  113. Post-PCI diameter stenosis in non-bifurcation target proximal edge segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in non-bifurcation target proximal edge segment

    Time frame: Baseline, just after final baseline procedure

  114. Post-PCI diameter stenosis in non-bifurcation target distal edge segment

    Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in non-bifurcation target distal edge segment

    Time frame: Baseline, just after final baseline procedure

07

Study locations

38 sites
08

References and documents

Publications

  • Holm NR, Andreasen LD, Neghabat O, Laanmets P, Kumsars I, Bennett J, Olsen NT, Odenstedt J, Hoffmann P, Dens J, Chowdhary S, O'Kane P, Bulow Rasmussen SH, Heigert M, Havndrup O, Van Kuijk JP, Biscaglia S, Mogensen LJH, Henareh L, Burzotta F, H Eek C, Mylotte D, Llinas MS, Koltowski L, Knaapen P, Calic S, Witt N, Santos-Pardo I, Watkins S, Lonborg J, Kristensen AT, Jensen LO, Calais F, Cockburn J, McNeice A, Kajander OA, Heestermans T, Kische S, Eftekhari A, Spratt JC, Christiansen EH; OCTOBER Trial Group. OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions. N Engl J Med. 2023 Oct 19;389(16):1477-1487. doi: 10.1056/NEJMoa2307770. Epub 2023 Aug 27. PubMed 37634149 ↗
  • Holm NR, Andreasen LN, Walsh S, Kajander OA, Witt N, Eek C, Knaapen P, Koltowski L, Gutierrez-Chico JL, Burzotta F, Kockman J, Ormiston J, Santos-Pardo I, Laanmets P, Mylotte D, Madsen M, Hjort J, Kumsars I, Ramunddal T, Christiansen EH. Rational and design of the European randomized Optical Coherence Tomography Optimized Bifurcation Event Reduction Trial (OCTOBER). Am Heart J. 2018 Nov;205:97-109. doi: 10.1016/j.ahj.2018.08.003. Epub 2018 Aug 16. PubMed 30205242 ↗

Individual participant data

Plan to share: Undecided — Is decided after primary endpoint assessment and requires regulatory approval

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Mar 2022, 56 months.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 56 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2017
First posted
May 31, 2017
StartActual
Jul 5, 2017
Primary completionActual
Mar 25, 2022
CompletionEst.
May 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03171311
Lead sponsor
Aarhus University Hospital Skejby
Collaborators
Abbott
Responsible party
Evald Hoej Christiansen (MD, phd, Aarhus University Hospital Skejby) — Principal investigator
First posted
May 31, 2017
Start date
Jul 5, 2017
Primary completion
Mar 25, 2022
Completion
May 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Evald H Christiansen, MD, PhD
study chair · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion